Rosuvastatin: Just Another Statin?
— · The Internet Journal of Cardiology · 2004
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
The Internet Journal of Cardiology · OpenAlex · article · 2004
Abstract
Convincing evidence exists supporting the major role HMG Co-A reductase inhibitors (statins) play in both primary and secondary prevention of cardiovascular diseases given, among other effects, their essential role in the reduction of LDL-C cholesterol . Recently revised guidelines recommend even more intense management of LDL-C cholesterol especially in moderate and high risk patients. Rosuvastatin, the newest statin, offers the most beneficial effects on the lipid profile and particularly, LDL-C. Its safety profile, both pre-approval and post-approval, at the current FDA-doses of 5-40mg is similar to other available statins.
Thus, rosuvastatin is an extremely helpful addition to the lipid armamentarium when prescribed at the current FDA approved doses.
Open the resolved locator · 10.5580/21be
Metadata licence: OpenAlex metadata (CC0)